Sarepta Therapeutics (NASDAQ: SRPT) reported Q3 EPS of ($0.63), $0.02 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Earnings

Sarepta (SRPT) Eteplirsen Delay Impacts DCF by $10/sh Each Year - Deutsche BankNovember 12, 2013 9:25 AM Piper Jaffray Downgrades Sarepta Therapeutic (SRPT) to UnderweightNovember 12, 2013 8:11 AM FDA Considers Sarepta's (SRPT) NDA for Eteplirsen 'Premature'November 12, 2013 7:05 AM